Nonhormonal vaginal lubricant

Phase 3Small molecule

Shionogi

Nonhormonal vaginal lubricant is one of 34 small molecule programs targeting Atrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

AtrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Atrophy

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

1 2

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 3

Activella

Eli Lilly

Phase 3

1 4

Pitocin

RRetrophin

Phase 3

4 5

Avandia

Alnylam Pharmaceuticals

Phase 2

1 6

Protease Inhibitor

MMedical Research Council

Approved

1 7

Protease Inhibitors

Tibotec Pharmaceuticals, Ireland

Approved

1 8

Avodart

Akero Therapeutics

Phase 2

1 9

Prometrium

Ferring

Phase 2

1 10

Genotropin

EMD Serono

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women

Completed· Shionogi logo

Shionogi·Phase 3·NCT00276094·826 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nonhormonal vaginal lubricant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nonhormonal vaginal lubricant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nonhormonal vaginal lubricant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shionogi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Shionogi

Nonhormonal vaginal lubricant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy1 trial

References

Drug Info

Quick Facts

Related News